NCT03486626Unknown4 期
Endometrial Thickness And Subendometrial Vascularity In Anovulatory Polycystic Ovarian Syndrome Patients Treated by Metformin
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 入组人数
- 85
- 试验地点
- 1
- 主要终点
- pregnancy
研究概览
简要总结
The participants will receive metformin 500mg 3times per day for 3months and one month is left for spontaneous pregnancy to occur or not (primary outcome ) and the investigators will check endometrial thickness and subendometerial vascularity as markers of endometrial receptivity before and after the treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 40 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •PCO syndrome patients have the following criteria:
- •Age of the patient between 20 - 40 years old. All subjects are not on a specific diet nor a certain program of physical exercise Complaining of infertility either primary or secondary due to PCOS.
- •N.B: The diagnosis of PCO syndrome was made according to the Androgen Excess and Polycystic Ovarian Syndrome Society: the presence of the following criteria have been required for the diagnosis of PCO syndrome:
- •Hyperandrogenism: Hirsutism and/or Hyperandrogenaemia Ovarian Dysfunction : Oligo-Anovulation and /or Polycystic ovaries Exclusion of other Androgen Excess or related disorders as :( deficient nonclassic adrenal hyperplasia, androgen-secreting neoplasms, androgenic/anabolic drug use or abuse, Cushing's syndrome, the Hyperandrogenic-Insulin Resistance-Acanthosis Nigricans syndrome, thyroid dysfunction, and hyperprolactinemia).
排除标准
- •Age below 20 or above
- •Women who intended to start a diet or a specific program of physical activity. Concurrent medical illness as cardiovascular, neoplastic and hepatic disorder. Pelvic pathology. Tubal, Uterine, Male factor of infertility. Endocrinological factors including: diabetes Mellitus,hypothyroidism, hyperprolactinaemia, Cushing's syndrome, and non- classical congenital adrenal hyperplasia.
- •Patients who are ovulatory during the ovarian cycle
研究组 & 干预措施
Patients
Experimental
干预措施: Metformin (Drug)
结局指标
主要结局
pregnancy
时间窗: 4 months
polycystic ovarian syndrome patients getting pregnant on receiving Metformin
次要结局
- Endometrial thickness and Sub Endometrial vascularity(4 months)
研究者
Mohamed Adel mohamed kamal Eldin Abdelrahman
Resident of Obstetrics and gynecology
Ain Shams Maternity Hospital
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Effect of metformin on the endometrium of obese, insulin-resistant womeobese, insulin-resistant womenJPRN-UMIN000015470Graduate School of Medicine, Chiba University15
已完成
早期 1 期
Metformin for the Treatment of Endometrial HyperplasiaEndometrial HyperplasiaEndometrial Hyperplasia Without AtypiaNCT01685762UNC Lineberger Comprehensive Cancer Center18
已完成
不适用
Endometrial Effects of Metformin Action in Women With Polycystic Ovarian Syndrome (PCOS)Polycystic Ovarian SyndromeNCT01070160Yale University14
已完成
3 期
PREMIUM (PRE-Surgical Metformin In Uterine Malignancies) studyTopic: CancerSubtopic: Gynaecological CancerDisease: Uterus/EndometriumCancerISRCTN88589234Central Manchester University Hospitals NHS Trust (CMFT)90
已完成
不适用
Metformin improves arterial stiffness in polycystic ovary syndrome (PCOS)Polycystic ovary syndromeNutritional, Metabolic, EndocrineOvarian dysfunctionISRCTN61785174Cardiff University (UK)32